Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen

NARIMOTO Kazutaka; MIZOKAMI Atsushi; IZUMI Kouji; MIHARA Shinya; SAWADA Kiyoshi; SUGATA Toshiaki; SHIMAMURA Masayoshi; MIYAZAKI Kimiomi; NISHINO Akio; NAMIKI Mikio

Art

J-GLOBAL ID：201002258156102474 Reference number：10A0360397

Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen

第二選択抗アンドロゲン,フルタミド併用アンドロゲン遮断療法を受けた去勢抵抗性前立腺癌患者の転帰予測因子としての副腎アンドロゲン濃度

Publisher site Copy service {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=10A0360397&COPY=1") }}
Access JDreamⅢ for advanced search and analysis. {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=10A0360397&from=J-GLOBAL&jstjournalNo=W1347A") }}

Author (10)： , , , , , , , , ,
Material：
Volume： 17 Issue： 4 Page： 337-345 Publication year： Apr. 2010
JST Material Number： W1347A ISSN： 0919-8172 Document type： Article
Article type：原著論文 Country of issue： Australia (AUS) Language： ENGLISH (EN)

,...
,...

To see more with JDream III (charged). {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=10A0360397&from=J-GLOBAL&jstjournalNo=W1347A") }}

Clinical application of antitumor(=antineoplastic)drugs , Sex hormones , Drug therapy(=pharmacotherapy)for tumors

, , ,

Reference (25)：

JEMAL, A. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59, 225-249
USAMI, M. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer : findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis. 2007, 10, 194-201
PIENTA, KJ. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res. 2006, 12, 1665-1671
NEWLING, DW. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer-Genitourinary Group Study 30853. Cancer. 1993, 72, 3793-3798
SCHER, HI. Bicalutamide for advanced prostate cancer : the natural versus treated history of disease. J. Clin. Oncol. 1997, 15, 2928-2938

ｍore...

, , , , , , , ,

Return to Previous Page